We use cookies to ensure that we deliver the best user experience of our website. If you would like to, you can change your cookie settings at any time. Continue

Dr Jane Steele

Director, Human Biomaterials Resource Centre

Medical and Dental Sciences

Contact details

Telephone +44 (0)121 414 7668 (tel:+44 121 414 7668)

Email j.c.steele@bham.ac.uk (mailto:j.c.steele@bham.ac.uk)

Human Biomaterials Resource Centre
Medical School
University of Birmingham
Edgbaston
Birmingham
B15 2TT
UK

About

Jane obtained a PhD from the University of Bath and worked as a Research Fellow in the UoB CRUK Institute of Cancer Studies for many years before moving to the Research Development Team within R&KT in January 2009.

She is now responsible for the establishment, development and management of the new Human Biomaterials Resource Centre (HBRC), and for providing advice on all aspects of compliance with the Human Tissue Act and the associated Codes of Practice. A key part of her role is to oversee and contribute to developing research programmes within, or connected to, the HBRC and to ensure the facility is at the forefront of technical advances in the field.

Qualifications

- PhD
- BSc (Hons) 2:1

Publications

- **Todd RW, Steele JC, Etherington I, and Luesley DM.** (2004) Detection of CD8+ T cell responses to human papillomavirus (HPV) type 16 antigens in women using imiquimod as a treatment for high grade vulval intraepithelial neoplasia (VIN). *Gynecol. Oncol.* 92(1):167-74
- **Sutton IJ, Steele J, Savage CO, Winer JB, and Young LS.** (2004) An interferon-□ ELISPOT and immunohistochemical investigation of cytotoxic T lymphocyte-mediated tumour immunity in patients with paraneoplastic cerebellar degeneration and anti-Yo antibodies. J. *Neuroimmunol.* 150(1-2):98-106
- **Steele JC, Mann CH, Rookes S, Rollason T, Murphy D, Freeth M, Gallimore PH, and Roberts S.** (2005) T-cell responses to human papillomavirus (HPV) type 16 antigens among women with different grades of cervical neoplasia. *Br. J. Cancer* 93(2):248-59
- **Steele JC, Torr E, Noakes KL, Kalk E, Moss PA Reynolds GM, Hubsher SG, van Lohuizen M, Adams DA, and Young LS** (2006) The polycomb group proteins, BMI-1 and EZH2, are tumour-associated antigens. *Br. J. Cancer* 95:1202-11
- **Steele J, Collins S, Wen K, Ryan G, Constandinou-Williams C, and Woodman CB** (2008) Measurement of the humoral immune response following an incident human papillomavirus type 16 or 18 infection in young women by a pseudovirion-based neutralizing antibody assay. *Clin. Vaccine Immunol.* 15:1387-90
- **Ahmed F, Steele JC, Herbert JM, Steven NM, and Bicknell R** (2008) Tumor stroma as a target in cancer. *Curr. Cancer Drug Targets* 6:447-53
- **Palmer DH, Midgley RS, Mirza N, Torr EE, Ahmed F, Steele JC, Steven NM, Kerr DJ, Young LS, and Adams DH** (2009) A phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma. *Hepatology* 49:124-32
- **Steele JC, Rao A, Armstrong CJ, Berhanse S, Billingham LJ, Graham N, Roberts C, Ryan G, Uppal H, Walker C, Young LS, and Steven NM** (2011) Phase I/II trial of a dendritic cell vaccine transfected with DNA encoding melan A and gp100 for patients with metastatic melanoma. *Gene Therapy*(in press).

© University of Birmingham 2014